cdef9a7f-9daa-4a33-b196-08a12a2ed203
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 69.3333333333333
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.620
- MYC_TARGETS_V1+0.600
- OXIDATIVE_PHOSPHORYLATION+0.560
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.510
- DNA_REPAIR+0.410
- E2F_TARGETS+0.390
- MTORC1_SIGNALING+0.370
- INTERFERON_ALPHA_RESPONSE+0.360
- CHOLESTEROL_HOMEOSTASIS+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.320
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- APICAL_SURFACE-0.320
- HEDGEHOG_SIGNALING-0.310
- UV_RESPONSE_DN-0.310
- PANCREAS_BETA_CELLS-0.300
- MYOGENESIS-0.290
- ANGIOGENESIS-0.280
- MITOTIC_SPINDLE-0.280
- KRAS_SIGNALING_DN-0.240
- TGF_BETA_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ddd65fce-1a39-415c-9114-7a9c8e9b266c | — | — | 0.891 |
| 2 | MNG602 | — | — | 0.882 |
| 3 | SRR17866821 | — | — | 0.875 |
| 4 | MNG510 | — | — | 0.873 |
| 5 | ERR2278852 | — | — | 0.863 |
| 6 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.862 |
| 7 | SRR11296765 | — | — | 0.859 |
| 8 | MNG277 | — | — | 0.851 |
| 9 | SRR6013558 | — | cohortA4 | 0.842 |
| 10 | TCGA-66-2758-01A-02R-0851-07 | — | cohortSQ2 | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.620 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.560 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.510 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.410 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |